NDC 73377-012-02 - Selegiline Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 73377-012
- Requested NDC
- 73377-012-02
- Package NDCs from labels
- 73377-012-01, 73377-012-02
- Manufacturer
- AX Pharmaceutical Corp
- Effective date
- 2020-02-04
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Selegiline Hydrochloride - AX Pharmaceutical Corp | AX Pharmaceutical Corp | 2020-02-04 | BULK INGREDIENT |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 73377-012-01 | Selegiline Hydrochloride | 500 g in 1 JAR | POWDER | 500 | 2 | |
| 73377-012-02 | Selegiline Hydrochloride | 100 g in 1 JAR | POWDER | 100 | 2 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | Golden State Medical Supply, Inc. | 040a97e5-efd1-4a2f-b737-2f13e5366d70 | 2025-11-24 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | Marlex Pharmaceuticals, Inc. | df88d6bf-0fda-3825-e053-2a95a90a3a75 | 2025-11-21 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | Bryant Ranch Prepack | b8eb0a00-adc7-4aaf-987c-fa1b207b2996 | 2025-08-18 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | Bryant Ranch Prepack | 4848270a-1179-410c-b4e6-a7e555b3a988 | 2025-07-15 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | A2A Integrated Pharmaceuticals | a59ff47b-4379-44f3-9d2c-f8c6121d1881 | 2025-02-28 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | Rising Pharma Holdings, Inc. | 23c4481f-d150-40c6-addb-b3e454ca914f | 2024-08-07 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | Chartwell RX, LLC | 189ac32d-28b4-47c5-9de6-318e502eff3b | 2024-05-08 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | i3 Pharmaceuticals, LLC | c81e983b-455d-2e65-e053-2a95a90a3123 | 2024-03-20 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | A-S Medication Solutions | f286c854-3b8c-44a8-b3b5-c828dbabb207 | 2023-02-06 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | Proficient Rx LP | 57b564ef-c89b-4cf6-a11f-f67391d74e7e | 2022-04-01 | Warnings, Adverse reactions | 6W731X367Q |
| ZELAPAR | SELEGILINE HYDROCHLORIDE | Bausch Health US, LLC | 380d7717-2a79-42f3-a712-efe5e7696ba0 | 2021-06-01 | Warnings, Adverse reactions | 6W731X367Q |
| Selegiline Hydrochloride | SELEGILINE HYDROCHLORIDE | Novitium Pharma LLC | e42d99b0-c62e-49d4-b792-1301bb539b92 | 2021-04-01 | Warnings, Adverse reactions | 6W731X367Q |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.